Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230
CTQJ230A12301
Phase 3 small_molecule active
Quick answer
Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230 for Cardiovascular Disease is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Cardiovascular Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active